Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.67 |
| ▸ | NPC1 | O15118 | 10/20 | 0.67 |
| ▸ | RAB9A | P51151 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8866403 | 0.99 | ALDH1A1 (0.66) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2128335 | 0.86 | RAB9A (0.71) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2127752 | 0.86 | ALDH1A1 (0.75) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2127570 | 0.85 | ALDH1A3 (0.65) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2127079 | 0.84 | NPC1 (0.74) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2126735 | 0.84 | NPC1 (0.72) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2127209 | 0.84 | NPC1 (0.76) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2127115 | 0.84 | ALDH1A1 (0.88) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2128899 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL2127861 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1RAB9AKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | claimed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | claimed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | claimed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | claimed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | claimed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | claimed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | disclosed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | disclosed |
| US-5614531-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | NOS1, PTGIS, NOS2 | ALDH1A1 1286/4885NPC1 2959/4885RAB9A 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.